

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  45D2113612	<b>(X3) Date Survey Completed</b>  04/09/2026
<b>Name of Provider or Supplier</b>  Eminent Medical Center, Llc	<b>Street Address, City, State</b>  1351 West President George Bush Hwy, Richardson, TX	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D0000</b>	An offsite proficiency testing desk review was conducted on 04/07/2026, and the following condition level deficiencies were cited: D2016 - 42 C.F.R. 493.803 Condition: Successful participation [proficiency testing] D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity testing; laboratory director
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on proficiency testing desk review of Centers for Medicare and Medicaid Services (CMS) 0155 report and American Proficiency Institute (API) 2025 proficiency testing (PT) records, the laboratory failed to successfully participate in the</p>

	<p>specialty of Routine Chemistry in Uric Acid analysis for two of three events in 2025 (Event 3) and 2026 (Event 1), resulting in an initial PT failure. Refer to D2096.</p>
<b>D2096</b>	<p><b>ROUTINE CHEMISTRY</b> CFR(s): 493.841(f)</p> <p>(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing (PT) records from the Certification and Survey Provider Enhanced Reporting (CASPER 0155 report and American Proficiency Institute (API) 2025 PT records, the laboratory failed to achieve an overall testing event score of satisfactory performance (80% or greater) for two of two consecutive testing events in the specialty of Routine Chemistry for Uric Acid analysis in 2025 (Event 3) and 2026 (Event 1), resulting in an initial PT failure. Findings included: 1. Review of the CASPER 0155 report revealed the following results: a. Routine Chemistry 2025-Third Event: Laboratory received an unsatisfactory score of 60% for Uric Acid analysis. b. Routine Chemistry 2026-First Event: Laboratory received an unsatisfactory score of 40% for Uric Acid analysis. 2. Review of the API Proficiency Testing records confirmed the laboratory received the above results in Routine Chemistry, for two of two consecutive proficiency testing events in 2025 (Event 3) and 2026 (Event 1), resulting in an initial PT failure.</p>
<b>D6000</b>	<p><b>MODERATE COMPLEXITY LABORATORY DIRECTOR</b> CFR(s): 493.1403</p> <p>The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.</p> <p>This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing (PT) records from the Certification and Survey Provider Enhanced Reporting (CASPER 0155 report and American Proficiency Institute (API) 2025 and 2026 PT records, the laboratory director failed to provide overall management and direction in accordance with 493.1445 of this subpart for one of one moderate complexity specialty (routine chemistry). Refer to D6016.</p>
<b>D6016</b>	<p><b>LABORATORY DIRECTOR RESPONSIBILITIES</b> CFR(s): 493.1407(e)(4)(i)</p> <p>(e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part;</p> <p>This STANDARD is not met as evidenced by: Based on a desk review of proficiency testing (PT) records from the Certification and Survey Provider Enhanced Reporting (CASPER 0155 report and American Proficiency Institute (API) 2025 PT records, the laboratory failed to achieve an</p>

overall testing event score of satisfactory performance (80% or greater) for two of two consecutive testing events in the specialty of Routine Chemistry for Uric Acid analysis in 2025 (Event 3) and 2026 (Event 1), resulting in an initial PT failure. Refer to D2096.